Targeting of antiviral drugs by coupling with protein carriers

Fiume, L.; Busi, C.; Mattioli, A.

doi:10.1016/0014-5793(83)80108-2

Cited by 25 publications

(8 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In order to reduce the systemic toxicity of DTX such as cumulative fluid retention25 as well as to avoid the use of toxic excipients such as tween80, which causes severe hypersensitive reactions2, 26; we used HSA chemically conjugated to the drug as a delivery system. This nonspecific carrier, which is easily distributed in tumor tissues and possesses a long plasma half‐life in vivo , has been extensively used as a carrier in the preparation of conjugates with antineoplastic27 or antiviral28 properties. The HSA was also very attractive for the derivatization of DTX, which is almost completely insoluble in water.…”

Section: Resultsmentioning

confidence: 99%

Docetaxel–Albumin Conjugates: Preparation, In Vitro Evaluation and Biodistribution Studies

Esmaeili

Dinarvand

Ghahremani

et al. 2009

Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Docetaxel–Albumin Conjugates: Preparation, In Vitro Evaluation and Biodistribution Studies

Esmaeili

Dinarvand

Ghahremani

et al. 2009

Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

“…The essentially rapid clearance of the glycoprotein lutropin is accounted for by signal-mediated endothelial cell homing to the liver [37,313]. The measured target specificity sets a shining precedent for work on drug delivery or radioimaging employing neoglycoproteins, synthetic matrices or liposomes as smart carriers [314][315][316][317][318][319][320][321][322][323][324][325][326][327][328][329]. This strategy exploits paradigmatically the natural capacity of cells like hepatocytes or macrophages to carry out lectin-dependent endocytosis [330][331][332][333][334][335][336].…”

Section: Review Articlementioning

confidence: 99%

Eukaryotic glycosylation: whim of nature or multipurpose tool?

Reuter¹,

Gabius²

1999

Cellular and Molecular Life Sciences (CMLS)

214

141

View full text Add to dashboard Cite

Protein and lipid glycosylation is a ubiquitous phenomenon. The task of cataloguing the great structural variety of the glycan part has demanded considerable efforts over decades. This patient endeavor was imperative to discern the inherent rules of glycosylation which cannot affirm assumptions on a purely coincidental nature of this type of protein and lipid modification. These results together with theoretical considerations uncover a salient property of oligosaccharides. In comparison with amino acids and nucleotides, monosaccharides excel in their potential to serve as units of hardware for storing biological information. Thus, the view that glycan chains exclusively affect physiochemical properties of the conjugates is indubitably flawed. This original concept has been decisively jolted by the discovery of endogenous receptors (lectins) for distinct glycan epitopes which are as characteristic as a fingerprint or a signature for a certain protein (class) or cell type. Recent evidence documents that these binding proteins are even endowed with the capacity to select distinct low-energy conformers of the often rather flexible oligosaccharides, granting entry to a new level of regulation of ligand affinity by shifting conformer equilibria. The assessment of the details of this recognition by X-ray crystallography, nuclear magnetic resonance spectroscopy, microcalorimetry and custom-made derivatives is supposed to justify a guarded optimism in satisfying the need for innovative drug design in antiadhesion therapy, for example against viral or bacterial infections and unwanted inflammation. This review presents a survey of the structural aspects of glycosylation and of evidence to poignantly endorse the notion that carrier-attached glycan chains can partake in biological information transfer at the level of cell compartments, cells and organs.

show abstract

“…Only by improving our understanding ofthe many factors involved in the disease process and undertaking concomitant studies on pharmacokinetics/pharmacodynamics will it become possible to design effective chemotherapeutic regimens. Technology is advancing regarding the targeting of drugs to the site of infection by using prod rugs (Krenitsky et al, 1984), by using protein carriers (Fiume et al, 1988), by modifying drugs to resist metabolic degradation, by use of liposomes or polymers to encapsulate/allow slow or pulse release (Canonico et al, 1984;Kende et al, 1985;Koff and Fidler, 1985). These advances in drug delivery will be of particular importance in veterinary practice, since repeated dosing is not always practicable or cost effective.…”

Section: Discussionmentioning

confidence: 99%

Prospects for Antiviral Chemotherapy in Veterinary Medicine: 2. Avian, Piscine, Canine, Porcine, Bovine and Equine Virus Diseases

Rollinson¹

1992

Antivir Chem Chemother

View full text Add to dashboard Cite

SummaryThis paper, which is published in two parts, reviews the literature pertaining to antiviral chemotherapy of viruses of veterinary importance. While early reports in the 1970s referred to the chemotherapy of a number of different RNA and DNA viruses, there' was considerable focus in the 1980s, initially on herpesviruses and latterly on retroviruses, and particularly in cats. Details are given of the successful treatments of FeLV and FIV, which have been used as animal models for HIV therapy. 'Therapy of equine, canine, bovine, porcine, avian, and fish diseases is also considered. The high costs of developing and registering a new chemical entity, especially for food species in which extensive toxicity/residue data are required, is the main reason why specific antiviral compounds are not currently available for veterinary use, although some non-specific immune modulators are now emerging. Concurrent availability of appropriate diagnostic tools is a prerequisite for successful veterinary antiviral chemotherapy, as is a greater understanding of the pathogenesis of virus infections in animals and the development of more sophisticated means of drug delivery, appropriate to both food animal species and companion animals (dogs, cats, and horses). Additionally, antiviral agents are valuable as research tools per se, as opposed to solely as chemotherapeutic agents. Part 1 covers the feline virus diseases, while part 2 includes the other viruses~f veterinary importance, in dogs, horses, cattle, pigs, birds, and fish.

show abstract

Targeting of antiviral drugs by coupling with protein carriers

Cited by 25 publications

References 44 publications

Docetaxel–Albumin Conjugates: Preparation, In Vitro Evaluation and Biodistribution Studies

Docetaxel–Albumin Conjugates: Preparation, In Vitro Evaluation and Biodistribution Studies

Eukaryotic glycosylation: whim of nature or multipurpose tool?

Prospects for Antiviral Chemotherapy in Veterinary Medicine: 2. Avian, Piscine, Canine, Porcine, Bovine and Equine Virus Diseases

Contact Info

Product

Resources

About